LY9

Creative Biolabs provides a one-stop solution for LY9-CART development. Our product line covers a wide range of anti-LY9 CAR-T vectors, viruses, cells, and reagents designed to facilitate your research. Please browse the list below to find the products you need.

Background

Ly-9, known as CD229, is a cell surface glycoprotein found on thymocytes, mature T and B cells, and NK cell subpopulations. LY9 is involved in many important processes, such as serving as a negative regulator of the development and homeostasis of thymus innate cell, and maintaining immune cell tolerance. Studies showed that LY9 is a useful prognostic biomarker and an attractive therapeutic target for many diseases.

Associated Diseases

• Multiple Myeloma
• B-Cell Malignancies

Anti-LY9 CAR-T Services

Anti-LY9 CAR-T In Vitro Assays

Anti-LY9 CAR-T Expression Test

In order to help our customers quickly identify the expression of specific CAR, we have developed a series of CAR detection reagents (e.g., sensitive fluoresce conjugated CAR detection products, Linker-targeted antibodies), as well as multiple experimental services for CAR expression verification via various approaches, such as qPCR, WB, flow cytometry.

Anti-LY9 CAR-T Proliferation Test

The verification of CART cell viability and proliferation is a very necessary test, which will provide an important reference for the subsequent CART function. Creative Biolabs conducts a variety of sensitive proliferation assays for CART cells, including MTT assay, CCK-8 assay, and CFSE-based test.

Fig.1 Expansion test of LY9 CAR-T cells detected by automated cell counting.¹

Anti-LY9 CAR-T Cytokine Release Test

Cytokine production and release is an important manifestation in the incubation process of CART cells and tumor cells. Creative Biolabs offers various robust detection assays to assess cytokine production and release, including multiplex bead arrays, enzyme-linked immunosorbent assays (ELISAs), and flow-based intracellular cytokine tests.

Fig.2 Cytokine secretion test of LY9 CAR-T cells co-cultured with primary plasma cell leukemia cells detected by cytometric bead assay.¹

Anti-LY9 CAR-T In Vitro Cytotoxicity Assay

In vitro cytotoxicity assay is designed to preliminarily verify the cytotoxic potential and specificity of CAR-T cells, providing many important references for further in vivo validation. We have developed a variety of methods for global customers to select the type that suits their project needs, including luciferase-based cytotoxicity test, flow cytometry cytotoxicity test, and real-time cell analysis (RTCA).

Fig.3 Cytotoxic activity test of LY9-CART cells against K562-CD229 tumor cells detected by luciferase-based cytotoxicity assay at indicated E: T ratio.¹

Anti-LY9 CAR-T In Vivo Assays

Anti-LY9 CAR-T Cell Therapy Animal Models

To meet the diverse needs of our customers' CART projects, we offer a range of animal models for anti-LY9 CART cell in vivo tests, including humanized, syngeneic, and xenograft models. These animal models are convenient for customers to quickly establish experimental schemes suitable for their projects, greatly speeding up the process of projects.

Efficacy Test of Anti-LY9 CAR-T

For in vivo efficacy testing of anti-LY9 CAR-T, Creative Biolabs has launched a variety of effective evaluation tests to assist in customers' projects, including but not limited to bioluminescence imaging, and in vivo dynamic analysis.

Fig.4 In vivo efficacy test of LY9 CAR-T cells in U-266 xenograft mouse model by BLI detection (Left panel) and survival record (Right panel).¹

Toxicity Evaluation Anti-LY9 CAR-T

To monitor the toxicity of LY9-CART treatment, such as the targeting of healthy LY9 expressing cells by LY9 CAR T cells, we provide various approaches to identify and characterize potential adverse events associated with the CART therapy, including phenotype analysis of in vivo model samples, off-toxicity studies, etc.

Fig.5 B-cell numbers analysis of the mouse models' peripheral blood (g) and bone marrow (h) after CART treatment.¹

Reference

1. Radhakrishnan, Sabarinath V., et al. "CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide." Nature communications 11.1 (2020): 798.